Vimarsana
Biggest News Aggregation in the World

Financial Data Tables News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Financial Data Tables. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Financial Data Tables Today - Breaking & Trending Today

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update - Vimarsana News

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

Published: May 2, 2024

First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530...

Source: marketscreener.com
Related Topics:
United StatesEmild KakkisDaiichi SankyoJoshua HigaDrug AdministrationContacts Ultragenyx Pharmaceutical IncExchange CommissionAmerican Academy Of Neurology MeetingUltragenyx Pharmaceutical IncUdall FoundationKyowa Kirin CoExpansion CohortsDose Escalation CohortFinancial Data TablesFinancial ResultsMonths Ended MarchLatin AmericaProfit Share TerritoryFinancial DataCash UsedNorth AmericaOsteogenesis ImperfectaAnnual American AcademyDose Escalation CohortsNatural History
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update - Vimarsana News

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Published: February 15, 2024

2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita...

Source: marketscreener.com
Related Topics:
United StatesDaiichi SankyoEmild KakkisJoshua HigaUltragenyx Pharmaceutical IncExchange CommissionEuropean Medicines AgencyContacts Ultragenyx Pharmaceutical IncTotal RevenueNet Cash UsedOsteogenesis ImperfectaFull YearFinancial Data TablesFinancial ResultsMonths Ended DecemberEnded DecemberLatin AmericaFinancial DataCash UsedNorth AmericaPriority MedicinesOrnithine TranscarbamylaseLooking StatementsPrivate Securities Litigation Reform ActKyowa Kirin